LONDON–(BUSINESS WIRE) – Curaleaf International (formerly EMMAC Life Sciences Group), Europe’s largest vertically integrated cannabis company, announces that its wholly-owned subsidiary Adven GmbH (“Adven”) has announced a strategic partnership with German subsidiary Zambon GmbH of Zambon Spa, a Italian multinational pharmaceutical company that is a leader in Parkinson’s, Severe Respiratory Diseases and Pain. The aim of the agreement is to provide medical cannabis treatments to patients with an initial focus on neurological therapies. The first treatment will be introduced in Germany in summer 2021.
“We are pleased to announce today this partnership with Zambon and to work with a leading pharmaceutical company to create the first European partnership for pharmaceutical and medicinal cannabis products. We believe this is a testament to our continued commitment to research-led product excellence at Curaleaf. is international, “says Antonio Costanzo, CEO of Curaleaf International. “We look forward to strengthening our collaboration and creating more such partnerships where relevant pharmaceutical and medical cannabis expertise and excellence can be combined to improve understanding of the medical cannabis industry for the rapidly growing European patient community.”
“Supportive therapies such as medical cannabis are a useful addition to Zambon’s European portfolio. Our expertise in neurology and the knowledge of Curaleaf International about the pharmaceutical active processes of cannabinoids offer ideal conditions to offer patients innovative treatments, ”says Marco Castino, Head of Region Europe in Zambon.
The market for medical cannabis in Germany
Cannabis has been approved for therapeutic use in Germany since 2017 and can be prescribed by doctors for serious illnesses. Germany is Europe’s largest market for medical cannabis. It is expected to be worth $ 2.1 billion1 by 2025.
“We are constantly looking for ways to improve the lives of chronically neurologically ill patients with our products. Offering modern therapeutic approaches such as comedication, especially in view of the progression of these clinical pictures, is part of our vision to improve patients. lives ”, says Dirk Greshake, managing director of Zambon GmbH.
“As a strategic partner, we bundle our experience and resources for the benefit of the patient. Together we want to advance the development of high-quality medical cannabis and have made it our task to improve the quality of life of neurological patients who still show symptoms despite conventional therapy. With the many years of experience of Zambon as a research company in the field of neurology and Adven GmbH, as part of Curleaf International, Europe’s largest vertically integrated company for medical cannabis with its extensive expertise in the development and production of medical cannabis, we see ourselves as a unique partnership to meet these patient needs, “explains Julian Vaterrodt, Managing Director of Adven GmbH.
About Curaleaf International
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe’s largest vertically integrated cannabis company, combining pioneering science and research with state-of-the-art cultivation, extraction and production. With a unique supply and distribution network across Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. For more information on Curaleaf International, please visit https://www.curaleafinternational.com/.
About Zambon Spa
Zambon is a multinational pharmaceutical company focused on innovation and development to improve patients’ lives. Based on a valuable heritage and strongly focused on the future, the goal is to improve people’s health by developing innovative and high quality health solutions. Zambon products are sold in 87 countries. The company has 23 subsidiaries on three different continents – Europe, America and Asia – and has production facilities in Italy, Switzerland, China and Brazil. The company now has a strong focus on rare disease treatment and specialties, in addition to respiratory disease, pain management, and feminine care. Zambon was founded in Italy in 1906 and today employs 2,400 people worldwide. For more information, please visit zambon.com.
All statements in this press release, other than historical facts, are forward-looking statements that involve various risks and uncertainties, including, but not limited to, statements about potential values, future plans, and goals of Curaleaf International. There can be no guarantee that such statements will prove to be correct, achievable or recognizable in the near future.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management at the time of their publication and are expressly restricted in their entirety by this release. Curaleaf International assumes no obligation to update any forward-looking statements should circumstances or management change its judgment or opinion.
1 brightfield group 2020